Literature DB >> 20868682

Effects of prostaglandin F(2α) analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprost.

Hiroaki Kurashima1, Hiroshi Watabe, Noriko Sato, Sanae Abe, Naruhiro Ishida, Takeshi Yoshitomi.   

Abstract

We investigated the effects of prostaglandin F(2α) (PGF(2α)) analogues on the endothelin-1 (ET-1)-induced impairment of optic nerve head (ONH) blood flow and on ET-1-induced contraction in isolated ciliary artery segments. In male rabbits, one of four PGF(2α) analogues [0.0015% tafluprost, 0.0015% 15-hydroxyl tafluprost (15-OH tafluprost), 0.005% latanoprost, or 0.004% travoprost] was topically administered at various pretreatment times before intravitreal ET-1 injection. ONH blood flow was estimated by the laser speckle method, which expresses blood velocity as a quantitative index, the squared blur rate (SBR). SBR was measured just before (baseline value) and at 30, 60, and 120 min after ET-1 injection. SBR was significantly decreased from 4.47 ± 0.20 to 3.50 ± 0.10 (78.6 ± 2.4% of baseline) at 120 min after intravitreal ET-1 injection (5 pmol/eye). The ET-1-induced decrease was almost completely prevented by tafluprost and significantly inhibited by the other three analogues. The inhibitory effect lasted longest with tafluprost, as indicated by the effective pretreatment times (tafluprost: 90, 120, or 240 min; 15-OH tafluprost: 90, but not 120 or 240 min; latanoprost and travoprost: 120, but not 240 min). In vitro, the effects of PGF(2α) analogues on ET-1-induced contractions in male rabbit ciliary arteries were evaluated using an isometric tension recording system. Tafluprost, latanoprost, travoprost, and 15-OH tafluprost concentration-dependently relaxed the 10 nM ET-1-induced ciliary artery contraction. Improvement of the ocular circulation may be superior with tafluprost than with the other PGF(2α) analogues. The underlying mechanism may involve relaxation of ocular resistance vessels.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20868682     DOI: 10.1016/j.exer.2010.09.004

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  21 in total

1.  Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action.

Authors:  Grace C Shih; David J Calkins
Journal:  Expert Rev Ophthalmol       Date:  2012-04

Review 2.  Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures.

Authors:  Chihiro Mayama; Makoto Araie
Journal:  Jpn J Ophthalmol       Date:  2013-01-16       Impact factor: 2.447

Review 3.  Endothelin antagonism as an active principle for glaucoma therapy.

Authors:  Rita Rosenthal; Michael Fromm
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

4.  Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries.

Authors:  Hiroshi Watabe; Sanae Abe; Takeshi Yoshitomi
Journal:  Jpn J Ophthalmol       Date:  2011-06-11       Impact factor: 2.447

5.  Effects of ripasudil hydrochloride hydrate (K-115), a Rho-kinase inhibitor, on ocular blood flow and ciliary artery smooth muscle contraction in rabbits.

Authors:  Yusuke Ohta; Sanae Takaseki; Takeshi Yoshitomi
Journal:  Jpn J Ophthalmol       Date:  2017-06-26       Impact factor: 2.447

6.  Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles.

Authors:  Yoo C Kim; Henry F Edelhauser; Mark R Prausnitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-11       Impact factor: 4.799

Review 7.  Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension.

Authors:  Gillian M Keating
Journal:  Clin Drug Investig       Date:  2016-06       Impact factor: 2.859

8.  Intraocular pressure fluctuation and neurodegeneration in the diabetic rat retina.

Authors:  Kyoung In Jung; Jung Eun Woo; Chan Kee Park
Journal:  Br J Pharmacol       Date:  2020-04-15       Impact factor: 8.739

9.  Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma.

Authors:  Yang Liu; Weiming Mao
Journal:  Clin Ophthalmol       Date:  2012-12-21

10.  Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma.

Authors:  Sıtkı Samet Ermiş
Journal:  Clin Ophthalmol       Date:  2012-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.